Eli Lilly has announced groundbreaking results for its experimental combination obesity treatment, reporting that eloraTZP achieved 23.3% average weight loss in patients battling both obesity or overweight and type 2 diabetes. The Indianapolis-based pharmaceutical giant revealed on Wednesday that this dual-drug cocktail outperformed its own blockbuster medication Zepbound in a head-to-head mid-stage trial, intensifying competition with Danish rival Novo Nordisk for dominance in the rapidly expanding obesity therapeutics market. Patients treated with the highest tested dose of eloraTZP demonstrated significantly superior outcomes compared to those receiving Zepbound alone, which achieved 14.8% weight loss at its highest dose over the same 48-week period. The combination therapy pairs eloralintide, an experimental amylin receptor agonist, with tirzepatide, the active ingredient in Lilly’s approved GIP/GLP-1 medication marketed as Zepbound for obesity and Mounjaro for diabetes. At the most potent dosing regimen-eloralintide 9 mg combined with Zepbound 15 mg-patients experienced an average weight reduction of 54.1 pounds from baseline at 48 weeks. The study also demonstrated meaningful metabolic benefits beyond weight reduction, with eloraTZP cutting blood sugar levels by lowering A1C by up to 2.9% compared to 2.4% for tirzepatide administered alone. Significance for Diabetic Obesity Treatment The results presented at the 62nd annual meeting of the European Association for the Study of Diabetes in Milan, Italy carry particular weight because patients with type 2 diabetes typically experience attenuated responses to obesity medications. Kenneth Custer, president of Lilly’s cardiometabolic health division, stated in an interview that he expected the combination drug would offer the best balance of efficacy, safety, and tolerability within Lilly’s obesity portfolio and among competitors. Analysts at Citi noted in a Wednesday client communication that the 23.3% average weight loss figure is both comparable to tirzepatide performance in patients without type 2 diabetes and notable given the efficacy attenuation typically seen with diabetes. The achievement exceeded Citi analyst expectations, with the results from the highest combination dose coming in comfortably above their 17% weight loss benchmark. Geoff Meacham, an analyst at Citi, emphasized that the findings provide strong combination proof-of-concept and broaden Lilly’s cardiometabolic portfolio beyond today’s incretin standards. Custer suggested it was possible the combination could lead to even greater weight loss in later trials than retatrutide, another promising Lilly experimental obesity medication that drove average weight reduction of up to 28.3% over 80 weeks in patients without diabetes in a late-stage trial. Triple-Hormone Mechanism of Action Lilly developed eloraTZP to activate three nutrient-stimulated hormones: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and amylin. These hormones function as key metabolic and hormone regulators produced in the gut and pancreas to control blood sugar, digestion, and appetite. Amylin, which is co-secreted with insulin by pancreatic beta-cells, has gained increasing attention recently as an obesity drug target because it works to slow digestion, block excess sugar production, and acts on the brain to signal satiety after eating. The mid-stage study enrolled 367 adults with obesity or overweight and type 2 diabetes, testing eloraTZP at different doses, plus each drug administered independently, against placebo. Lilly based its interpretation on the efficacy estimand, which represents the efficacy had all randomized participants taken their study treatment as directed for 48 weeks. Based on the positive readout, Lilly plans to initiate phase 3 trials with eloraTZP in 2026’s fourth quarter, moving the experimental therapy closer to potential regulatory approval and commercial availability. Safety Profile and Discontinuation Concerns Despite the strong efficacy data, Lilly shares fell marginally as investors focused on adherence patterns and long-term persistence challenges associated with the dual-drug regimen. Patients discontinued eloraTZP treatment at rates ranging from 10.8% to 27%, depending on the severity of side effects as multiple doses were tested throughout the trial. That discontinuation range compared with a dropout rate of 0% to 10.8% with eloralintide administered alone, 2.9% for tirzepatide monotherapy, and 16.7% for participants who received placebo injections. “The outsized weight loss benefit is being questioned relative to the discontinuation rates and the reality that this is a dual-drug regime,” said Kevin Gade, COO at Bahl & Gaynor, which holds Lilly shares. The most common side effects documented in the trial were mild to moderate gastrointestinal issues that occurred mainly during dose escalation and were more frequent in the combination treatment arms. These tolerability patterns mirror those seen with other incretin-based obesity medications, though the higher discontinuation rates at certain dose levels may prompt Lilly to optimize dosing strategies before advancing to phase 3 development. Competitive Landscape in Obesity Therapeutics The eloraTZP data emerge as Lilly intensifies its competition with Novo Nordisk for leadership in the multibillion-dollar obesity treatment market. Lilly reported topline data from a phase 3 retatrutide trial in July, with full results also presented this week at the EASD meeting showing that 34.9% of patients given retatrutide 12 mg lost at least 25% of their body weight. The pharmaceutical giant’s expanding obesity pipeline now includes multiple mechanisms of action, positioning the company to potentially offer differentiated treatment options for diverse patient populations with varying metabolic profiles and comorbid conditions. The combination approach represents a strategic bet that activating multiple hormonal pathways simultaneously will deliver superior outcomes compared to single-mechanism therapies. By pairing its approved tirzepatide franchise with the experimental amylin agonist, Lilly aims to address the substantial unmet need among patients with both obesity and type 2 diabetes-a population that historically responds less robustly to weight-loss interventions. The forthcoming phase 3 program will provide definitive evidence on whether eloraTZP can maintain its efficacy advantage in larger, more diverse patient cohorts while demonstrating an acceptable safety and tolerability profile for chronic administration. Post navigation Medical Ethics Clash With Death Penalty as States Face Execution Drug Crisis Texas Hospitals Fail to Protect Low-Income Patients From Medical Debt, Investigation Finds